Compare IH & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IH | ARMP |
|---|---|---|
| Founded | 1996 | N/A |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 84.1M | 295.5M |
| IPO Year | 2020 | 1996 |
| Metric | IH | ARMP |
|---|---|---|
| Price | $1.64 | $8.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 8.9K | ★ 69.0K |
| Earning Date | 03-31-2026 | 05-07-2026 |
| Dividend Yield | ★ 5.88% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $7.30 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.55 | $1.74 |
| 52 Week High | $3.60 | $14.98 |
| Indicator | IH | ARMP |
|---|---|---|
| Relative Strength Index (RSI) | 43.63 | 42.01 |
| Support Level | $1.55 | $7.22 |
| Resistance Level | $1.83 | $12.11 |
| Average True Range (ATR) | 0.06 | 0.92 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 15.31 | 49.17 |
iHuman Inc is a Chinese company that uses artificial intelligence to create technology-driven puzzle products for children, making parenting easier and children happier. The company offers a range of intellectual development products that are designed to make the child-rearing experience more manageable for parents while turning intellectual development into a fun journey for children. Its revenue is generated from subscription fees paid by users for premium content on their self-directed and interactive online applications, as well as offline products and other sources. All of the groups revenue is generated from Chinese Mainland.
Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.